DR. JOHN T. GANEY, MD

ANTIOCH, CA

Research Active
Internal Medicine - Hematology & Oncology NPI registered 21+ years 2 publications 2018 – 2021 NPI: 1215935713
Internal Medicine - Hematology & Oncology
MiceCRISPR-Cas SystemsCells, CulturedAdenineCholesterol, LDL

Practice Location

4721 DALLAS RANCH ROAD
ANTIOCH, CA 94531-8811

Phone: (925) 778-0679

What does JOHN GANEY research?

John D Ganey studies the use of CRISPR technology, which is a powerful tool that allows scientists to edit genes within living organisms. Specifically, he is exploring how altering the PCSK9 gene, which plays a vital role in cholesterol production, can reduce cholesterol levels significantly. His research primarily addresses conditions related to high cholesterol and aims to provide long-term treatments that could eliminate the need for regular cholesterol medications.

Key findings

  • A single CRISPR injection in monkeys resulted in a 60% reduction in cholesterol levels.
  • The lowered cholesterol levels remained significantly reduced for at least 8 months without additional treatment.
  • This gene-editing approach suggests a potential one-time treatment option for patients with heart disease.

Frequently asked questions

Does Dr. Ganey study high cholesterol?
Yes, Dr. Ganey focuses on high cholesterol and how gene editing can provide long-lasting solutions.
What treatments has Dr. Ganey researched?
He has researched CRISPR-based gene editing as a treatment for lowering cholesterol.
Is Dr. Ganey's work relevant to heart disease patients?
Yes, his research aims to offer new treatments for patients with heart disease related to high cholesterol.

Publications in plain English

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.

2021

Nature

Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE +37 more

Plain English
Researchers used a gene-editing tool called CRISPR to permanently disable a gene in monkeys' livers that controls cholesterol production, delivering it through tiny fat particles injected into the bloodstream. After a single injection, the monkeys' cholesterol dropped by about 60% and stayed low for at least 8 months without any additional treatment. This proves that gene editing could offer heart disease patients a one-time treatment instead of taking cholesterol drugs for life.

PubMed

Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.

2018

Journal of cachexia, sarcopenia and muscle

Kandarian SC, Nosacka RL, Delitto AE, Judge AR, Judge SM +3 more

Plain English
This study looked at how a substance produced by certain cancer cells, called leukaemia inhibitory factor (LIF), contributes to a wasting syndrome known as cancer cachexia in mice. Researchers created a modified version of the cancer cells without LIF and found that mice with these modified cells experienced 55-75% less weight loss, muscle loss, and fat loss compared to those with regular cancer cells. This matters because understanding how LIF drives cachexia can help develop new treatments to improve the quality of life for cancer patients. Who this helps: This helps patients suffering from cancer cachexia.

PubMed

Frequent Co-Authors

Kiran Musunuru Alexandra C Chadwick Taiji Mizoguchi Sara P Garcia Jamie E DeNizio Caroline W Reiss Kui Wang Sowmya Iyer Chaitali Dutta Victoria Clendaniel

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.